M&A / Deals Jazz orchestrates a $4bn cancer alliance with AbCellera PharmaphorumJazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera.OncologyRead full story pharminent June 17, 2026 (Last updated: June 17, 2026) Pharmaphorum Jazz Pharma has made a big move into T-cell engagers (TCEs) for solid tumours, via an alliance with Canadian biotech AbCellera. Oncology Read full story Post navigation Previous: Edgewise slides as cardiomyopathy challenger to BMS, Cytokinetics falls shortNext: uniQure sets course to US filing for Huntington gene therapy Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026